Related Experiment Video
Updated: Jun 19, 2026
07:30
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
Management of Guillain-Barré syndrome
1Department of Neurology, Pathology 509, Johns Hopkins Hospital, 600 N-Wolfe Street, Baltimore, MD 21287, USA.
Expert Review of Neurotherapeutics
|October 9, 2009
Summary
Guillain-Barré syndrome, a leading cause of acute flaccid paralysis, benefits from supportive care and early immune therapies like plasmapheresis or IV immunoglobulin to improve patient recovery outcomes.
Area of Science:
- Neurology
- Immunology
- Critical Care Medicine
Background:
- Guillain-Barré syndrome is the primary cause of acute flaccid paralysis.
- While intensive care has lowered mortality, significant disability persists in some patients.
- This condition is an immune-mediated neuropathy.
Purpose of the Study:
- To summarize the current management strategies for Guillain-Barré syndrome.
- To outline both supportive and immune-modulating therapies.
- To provide an overview of Guillain-Barré syndrome treatment.
Main Methods:
- Review of current medical literature on Guillain-Barré syndrome management.
- Summary of supportive care protocols.
- Analysis of evidence for plasmapheresis and intravenous immunoglobulin efficacy.
Main Results:
- Supportive medical care is crucial for managing Guillain-Barré syndrome.
- Plasmapheresis and intravenous immunoglobulin can accelerate recovery if administered early.
- Despite advances, mortality remains up to 5%, with 10% experiencing long-term walking difficulties.
Conclusions:
- Effective management of Guillain-Barré syndrome involves a combination of supportive care and early immune-based interventions.
- Prompt treatment with plasmapheresis or IV immunoglobulin is recommended for hastening recovery.
- Continued research and optimized care are essential to further reduce mortality and disability from Guillain-Barré syndrome.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
01:22Botulism
Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...